StockIQpro
NASDAQ:QNCX

Quince Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Quince Therapeutics, Inc. reported net income of −$84.0M in fiscal 2025. Free cash flow was −$41.8M, and the diluted share count rose 15.8%.Summary generated from Quince Therapeutics, Inc.'s SEC filings. Latest annual report filed Apr 10, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$41.8M
FCF marginn/a
Share count change+15.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−90−52−35−57−58
Net income−90−52−31−57−84
Free cash flow−63−44−18−32−42

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)